• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

This Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2008 is Now Available

Posted on: Friday, 7 November 2008, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/research/f9f2a7/pharmaceutical_pri) has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2008" to their offering.

Governments in Europe and Japan have long exercised strict control over prices in their national pharmaceutical markets, and they give every indication of tightening their grip on drug manufacturers. Recent evidence suggests that U.S. politicians and payers are devoting unprecedented attention to measures to curb spending in the world's largest pharmaceutical market, a disturbing turn of events for manufacturers of branded drugs.

Get the Answers You Need to Shape Your Strategy

- U.S. employers are altering their formulary designs and increasing their use of utilization management tools. What are the most common formulary designs in 2008? What out-of-pocket payments are employers requiring their employees to make for prescription drugs? Which cost-containment measures are becoming more common in the United States?

- The French government has announced plans for healthcare reforms in its 2009 budget. How will the pricing of generic drugs change? What measures are proposed to expand the scope of the reference pricing system? How will the funding of high-priced drugs in the hospital sector change?

- The implementation of healthcare reforms passed in Germany in 2007 is progressing slowly. Which drug class will be the first subjected to a requirement for a second opinion from a qualified specialist? What is the timetable for implementation of health economic evaluation? What measure is the German government considering to recoup money lost by the statutory health insurance system as a result of the delays in introducing maximum reimbursement sums?

- The U.K. government prematurely terminated the 2005 Pharmaceutical Price Regulation Scheme (PPRS) on August 31, 2008. What plans does the government have for a new system in 2009? What interim measures have been implemented pending the introduction of the new PPRS?

Key Topics Covered:

Executive Summary

-Strategic Considerations

-Stakeholder Implications

Overview

United States

-Unexpected Decline in the Ranks of the Uninsured

-Drug Benefit Trends

-Medicare Reforms

-Call for Medicare Part D Discounts to Match Savings Available to Medicaid

France

-Market Trends

-Reforms Proposed for 2009

Germany

-Continued Growth of Rebate Contracts

-Slow Progress on Implementation of Reforms Passed in 2007

--Second Opinion Process

--Health Economic Evaluation

--Maximum Reimbursement Sums

-New Reference Price Groups

Italy

-Market Trends

Spain

-Amendments to the Reference Pricing System

-Proposals to Facilitate Patient Access to Novel Drugs

United Kingdom

-Reform of the Pharmaceutical Price Regulation Scheme

-Renewed Criticism of NICE

Japan

-Industry Proposal for Pricing Reform

-Measures to Stimulate the Generics Market

-Resistance to Calls for Introduction of Reference Pricing

Outlook and Implications for the Pharmaceutical Industry

For a comprehensive list of companies mentioned please follow the link provided.

For more information visit http://www.researchandmarkets.com/research/f9f2a7/pharmaceutical_pri

Source: Business Wire

More News in this Category